[
  {
    "ts": null,
    "headline": "Personalis price target raised to $8 from $7 at BTIG",
    "summary": "BTIG raised the firm’s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note. The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the",
    "url": "https://finnhub.io/api/news?id=3749a32f7b1a230d3f9267e720ec0212a66be586fdf2fcdc7710774eaa46c089",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734784252,
      "headline": "Personalis price target raised to $8 from $7 at BTIG",
      "id": 132097271,
      "image": "",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BTIG raised the firm’s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note. The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the",
      "url": "https://finnhub.io/api/news?id=3749a32f7b1a230d3f9267e720ec0212a66be586fdf2fcdc7710774eaa46c089"
    }
  },
  {
    "ts": null,
    "headline": "Merck closes exclusive global license agreement for LM-299 from LaNova Medicines",
    "summary": "Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588M, or approximately 18c per share, in the company’s fourth quarter 2024 GAAP and non-GAAP results. LaNova is also eligible to receive up to $2.7B in milestone payments associate",
    "url": "https://finnhub.io/api/news?id=64e8a44f377167c2cad3104a0a6458ba8981efc00849273a805cb5fc312216a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734781835,
      "headline": "Merck closes exclusive global license agreement for LM-299 from LaNova Medicines",
      "id": 132097274,
      "image": "https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines. As previously announced, Merck will develop, manufacture and commercialize LM-299. Merck will record a pre-tax charge relating to the upfront payment of $588M, or approximately 18c per share, in the company’s fourth quarter 2024 GAAP and non-GAAP results. LaNova is also eligible to receive up to $2.7B in milestone payments associate",
      "url": "https://finnhub.io/api/news?id=64e8a44f377167c2cad3104a0a6458ba8981efc00849273a805cb5fc312216a1"
    }
  },
  {
    "ts": null,
    "headline": "If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy",
    "summary": "The methodology uses earnings yield, dividend yield, and 5-year dividend CAGR to score and rank 55 stocks across all 11 sectors.",
    "url": "https://finnhub.io/api/news?id=d5eae36fb2c4b242a6ff797ba27a3c5c004e126d305bd97ae5534840b428cb85",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734773400,
      "headline": "If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy",
      "id": 132095841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810148/image_1445810148.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "The methodology uses earnings yield, dividend yield, and 5-year dividend CAGR to score and rank 55 stocks across all 11 sectors.",
      "url": "https://finnhub.io/api/news?id=d5eae36fb2c4b242a6ff797ba27a3c5c004e126d305bd97ae5534840b428cb85"
    }
  }
]